Pikin O V, Ryabov A B, Shcherbakova N I, Glushko V A, Kolbanov K I, Barmin V V, Aleksandrov O A, Bagrov V A, Khrushcheva N A, Salimov Z M, Martynova D E
Herzen Research Institute of Oncology, Moscow, Russia.
Neurology Research Centre, Moscow, Russia.
Khirurgiia (Mosk). 2021(9):27-33. doi: 10.17116/hirurgia202109127.
To analyze efficacy and safety of rethymectomy in patients with pathology of thymus.
Nine patients (2 males and 7 females) underwent rethymectomy in the thoracic surgery department of the Hertzen Research Institute of Oncology for the period from March 2009 to December 2019. Initial thymectomy for myasthenia gravis was performed in 6 patients, for thymoma without myasthenia - in 3 patients. Age of patients varied from 27 to 75 years (median 42.8 years). Myasthenia manifested at the age of 25-61 years (median 29.2 years). Period between manifestation and thymectomy varied from 6 to 24 months (median 12.6 months). MGFA grade IIIa was in 1 patient, grade IIIb - in 1, grade IVa - in 1, grade IVb - in 2, grade V - in 1 patient. Rethymectomy was performed via sternotomy in 4 cases, through thoracoscopy - in 5 patients.
Postoperative complications occurred in 2 (22.2%) patients. Biopsy revealed residual thymic tissue in all patients. Median follow-up after rethymectomy was 30.2 months (range 12-132 months). Complete stable remission was achieved in 3 (50.0%) patients, remission - in 2 cases, partial remission - in 1 patient. Median dose of steroids before rethymectomy was 40 mg (range 16-96 mg), median dose after rethymectomy - 8 mg (range 0-24 mg). Differences were significant (=0.04). All patients operated on for thymoma or recurrence are alive within 12-124 months after rethymectomy.
Rethymectomy is a safe and effective treatment option for patients with refractory myasthenia gravis (especially in case of detected residual thymic tissue) or recurrent thymoma. Radical surgery for recurrent thymoma ensures favorable survival.
